This depends on the sample but can include; patient characteristics, Spirometry (FEV1), medication including long-term antibiotics, sample type, clinical state and microbiological status.
Working with researchers to develop new antibiotics for CF infections.
With our funding, we offer a collaborative approach to project development and delivery.
Our collaborative network accelerates CF antimicrobial development.
Learn more about the CF AMR Syndicate and the work we do.
Working with researchers to develop new antibiotics for CF infections.
With our funding, we offer a collaborative approach to project development and delivery.
Our collaborative network accelerates CF antimicrobial development.
Learn more about the CF AMR Syndicate and the work we do.